A Phase 3 interventional study of Tradipitant and Placebo in Atopic Dermatitis, sponsored by Vanda Pharmaceuticals. Completed at 70 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-05-13.
Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 92nd largest by enrollment of the 544 interventional ones that give a count, is one of 56 that started in 2018, is one of 103 in phase 3, and was the 269th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 56 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 375 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 4 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
43 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 43 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tradipitant
Drug: Placebo
Oral Capsule
Oral Capsule
Reduction of Worst Itch in Atopic Dermatitis
Reduction of worst itch in atopic dermatitis as measured by Numerical Rating Scale (NRS). Worst Itch NRS is an assessment tool that is used to report the maximum intensity of participant's itch during a 24-hour recall period. Participants were asked the following question: Please rate the itching severity that describes your worst level of itching in the past 24 hours \[0=No Itch, 10=Worst Itch Imaginable\].
Time frame: 8 weeks
Improvement of Disease Severity in Atopic Dermatitis
Proportion of participants achieving 50% reduction on the SCORing Atopic Dermatitis (SCORAD) index. SCORAD is an assessment scale used to determine the severity of AD. SCORAD combines the investigator's rating of extent and intensity and the patient reported itch and sleep disturbance. Total score ranges from 0 (absent disease) to 103 (severe disease).
Time frame: 8 weeks
Proportion of Patients With Improvement on Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of at Least 2-point Reduction
As measured by the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD). IGA is an assessment scale used to determine severity of AD. It is assessed by the investigator on a 5-point scale (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe) based on erythema, induration/papulation, lichenification, and oozing/crusting.
Time frame: 8 weeks
| Milestone | Tradipitant | Placebo |
|---|---|---|
| Started | 188 | 187 |
| Completed | 142 | 144 |
| Not completed | 46 | 43 |
Reduction of worst itch in atopic dermatitis as measured by Numerical Rating Scale (NRS). Worst Itch NRS is an assessment tool that is used to report the maximum intensity of participant's itch during a 24-hour recall period. Participants were asked the following question: Please rate the itching severity that describes your worst level of itching in the past 24 hours \[0=No Itch, 10=Worst Itch Imaginable\].
| units on a scale | Tradipitant | Placebo |
|---|---|---|
| Reduction of Worst Itch in Atopic Dermatitis | -3.6 ± 2.8 | -3.5 ± 2.75 |
Proportion of participants achieving 50% reduction on the SCORing Atopic Dermatitis (SCORAD) index. SCORAD is an assessment scale used to determine the severity of AD. SCORAD combines the investigator's rating of extent and intensity and the patient reported itch and sleep disturbance. Total score ranges from 0 (absent disease) to 103 (severe disease).
| Participants | Tradipitant | Placebo |
|---|---|---|
| Improvement of Disease Severity in Atopic Dermatitis | 51 | 54 |
As measured by the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD). IGA is an assessment scale used to determine severity of AD. It is assessed by the investigator on a 5-point scale (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe) based on erythema, induration/papulation, lichenification, and oozing/crusting.
| Participants | Tradipitant | Placebo |
|---|---|---|
| Proportion of Patients With Improvement on Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of at Least 2-point Reduction | 37 | 36 |
Worst Itch NRS is an assessment tool that is used to report the maximum intensity of participant's itch during a 24-hour recall period. Participants were asked the following question: Please rate the itching severity that describes your worst level of itching in the past 24 hours \[0=No Itch, 10=Worst Itch Imaginable\].
| units on a scale | Tradipitant | Placebo |
|---|---|---|
| Reduction of Worst Itch in Atopic Dermatitis as Measured by Numerical Rating Scale (NRS), Adjusted for Investigator Global Assessment (IGA) | -2.6 (-3.2 to -2.0) | -1.0 (-1.6 to -0.4) |
SCORAD is an assessment scale used to determine the severity of AD. SCORAD combines the investigator's rating of extent and intensity and the patient reported itch and sleep disturbance. Total score ranges from 0 (absent disease) to 103 (severe disease).
| units on a scale | Tradipitant | Placebo |
|---|---|---|
| Reduction in Sleep Disturbances as Measured by SCORing Atopic Dermatitis Index, Adjusted for Investigator Global Assessment | -2.07 (-2.61 to -1.53) | -0.7 (-1.24 to -0.15) |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent up to the final visit (Week 8) regardless of seriousness or relationship to investigational product. Patients with non-serious AEs that are ongoing at the patient's last study visit must be followed until resolution or for 30 days after the patient's last study visit, whichever comes first.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tradipitant | 0/188 (0%) | 2/188 (1.1%) | 23/188 (12.2%) |
| Placebo | 0/187 (0%) | 1/187 (0.5%) | 11/187 (5.9%) |
| Event | Tradipitant | Placebo |
|---|---|---|
| Extradural abscessInfections and infestations | 0/188 | 1/187 |
| ChokingRespiratory, thoracic and mediastinal disorders | 1/188 | 0/187 |
| Dyshidrotic eczemaSkin and subcutaneous tissue disorders | 1/188 | 0/187 |
| Event | Tradipitant | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 7/188 | 4/187 |
| HeadacheNervous system disorders | 7/188 | 5/187 |
| DiarrhoeaGastrointestinal disorders | 5/188 | 1/187 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 4/188 | 1/187 |
| Age, Continuous(years) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Mean | 41.7 ± 14.9 | 41.9 ± 15.1 | 41.8 ± 15.0 |
| Sex: Female, Male(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Female | 124 | 119 | 243 |
| Male | 64 | 68 | 132 |
| Ethnicity (NIH/OMB)(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 42 | 46 | 88 |
| Not Hispanic or Latino | 144 | 140 | 284 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 |
| Race — Asian | 10 | 12 | 22 |
| Race — Black or African American | 51 | 45 | 96 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 3 | 4 |
| Race — White | 123 | 123 | 246 |
| Race — Other | 3 | 4 | 7 |
| Region of Enrollment(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| United States | 188 | 187 | 375 |
| Worst Itch Numeric Rating Scale (NRS) Score(units on a scale) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Mean | 8.2 ± 1.2 | 8.1 ± 1.3 | 8.2 ± 1.3 |
| SCORing Atopic Dermatitis (SCORAD) Index(units on a scale) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Mean | 49.56 ± 14.5 | 50.76 ± 14.0 | 50.16 ± 14.3 |
| Validated Investigator's Global Assessment scale for atopic dermatitis (vIGA-AD) Score(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Almost Clear (1) | 2 | 0 | 2 |
| Mild (2) | 38 | 39 | 77 |
| Moderate (3) | 113 | 105 | 218 |
| Severe (4) | 18 | 26 | 44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Dec 2019, 17 months.
Results were first posted in May 2024, 4 years 4 months after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 17 months is close to that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tradipitant